\
&
Contact us
The New European Bauhaus is a creative and interdisciplinary initiative that connects the European Green Deal to our living spaces and experiences.
The New European Bauhaus initiative calls on all of us to imagine and build together a sustainable and inclusive future that is beautiful for our eyes, minds, and souls. Beautiful are the places, practices, and experiences that are:
This initiative also wants to create a new community and movement in the European Union by bringing citizens, experts, businesses, and institutions together to reimagine sustainable living in Europe and beyond.
From 2025 onwards the New European Bauhaus is set to have its first-ever multiannual funding tool, the New European Bauhaus Facility, that aims to revitalise neighbourhoods through design for sustainability and inclusion. It is a cross-cutting tool that combines different funding instruments of the Commission and covers the full cycle of implementation of solutions – from research and innovation to deployment – through its two components:
manhei.to@fwo.be
+32 2 550 15 55
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.